AB038. SOH21AS053. Endovascular unibody aortic grafts versus covered endovascular reconstruction of the aortic bifurcation (CERAB) technique for the management of aorto-iliac occlusive disease—a systematic review
Vascular Session

AB038. SOH21AS053. Endovascular unibody aortic grafts versus covered endovascular reconstruction of the aortic bifurcation (CERAB) technique for the management of aorto-iliac occlusive disease—a systematic review

Dzmitry Hetmanau1, Ailbhe NiGhriofa1, Mahmoud Alawy1, Wael Tawfick1,2, Muhammad Tubassam1, Stewart Walsh1

1Department of Vascular and Endovascular Surgery, University Hospital Galway, Galway, Ireland; 2School of Medicine, University Hospital Galway, Galway, Ireland

Background: Aortoiliac occlusive disease (AIOD) can adversely affect patients leading to life-limiting critical limb ischemia (CLI). Peri-operative morbidity is significant in open surgical repair. Endovascular alternatives include covered endovascular reconstruction of the aortic bifurcation (CERAB) or unimodular aortic endografts

Methods: A systematic review of articles was conducted following PRISMA guidelines, searching PubMed, Embase and CINAHL databases. We searched randomized-controlled trials, clinical-controlled trials and observational studies, looking at patients with CLI due to TASC-C/D AIOD. Outcomes included patency rates, re-intervention rates, amputation-free survival and adverse events

Results: Two hundred and eighty articles were identified. After removal of duplicates and screening of titles and abstracts, 20 full-text articles were screened. Three articles met the full inclusion and exclusion criteria and were included in the study. Forty-nine patients were treated with Unibody Aortic Endografts (age 59 to 67.9 years). Thirty-seven (75.5%) patients had Rutherford 4 symptoms and 12 had Rutherford 5–6. Forty-four (88%) patients had TASC-D lesions. Fifty-nine patients were managed with CERAB (age 61 to 67 years). Technical success occurred in 100% of Unibody cases. Primary patency ranged from 80–100%, Amputation-free survival: 99–100%, re-intervention rates 0–20%, Secondary patency was 100% in all cases, Quality of life improved in 73–100% of cases. Thirty-day mortality included only one patient. All articles reporting on CERAB included claudicants and CLI patients

Conclusions: Unibody Aortic Endografts for treatment of AIOD in patients with CLI are safe, with lengthy patency rates and exceptional limb salvage.

Keywords: Aortoiliac occlusive disease (AIOD); critical limb ischaemia (CLI); unimodular aortic endografts; covered endovascular reconstruction of the aortic bifurcation (CERAB)

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-21-ab038
Cite this abstract as: Hetmanau D, NiGhriofa A, Alawy M, Tawfick W, Tubassam M, Walsh S. SOH21AS053. Endovascular unibody aortic grafts versus covered endovascular reconstruction of the aortic bifurcation (CERAB) technique for the management of aorto-iliac occlusive disease—a systematic review. Mesentery Peritoneum 2021;5:AB038.

Article Options

Download Citation

Share